Empresa Lonza Group AG Börse Stuttgart
Acciones
LO3A
US54338V1017
Biotecnología e investigación médica
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
50 EUR | +1,21 % |
|
+1,63 % | +35,87 % |
Resumen de negocios
- biofarmacéuticos (55,4%): síntesis exclusivas, productos de fermentación microbiológica , cultivos de células de mamíferos, etc;
- cápsulas y soluciones de dosificación para biofármacos, medicamentos y productos de nutrición (17,3%). Además, el grupo ofrece ingredientes nutricionales
- sustancias farmacéuticas de moléculas pequeñas (13,4%);
- tecnologías y plataformas para procesos de fabricación y producción de terapias celulares y génicas (10,4%);
- otros (3,5%).
Las ventas netas se distribuyen geográficamente de la siguiente manera: Suiza (17,4%), Europa (31,7%), Estados Unidos (31,8%), América (3,2%), Japón (8,1%), Asia (7,5%) y otros (0,3%).
Ventas por actividad
CHF en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Biologics
55,4
%
| 3 274 | 52,6 % | 3 719 | 55,4 % | +13,59 % |
Capsules & Health Ingredients
17,3
%
| 1 266 | 20,3 % | 1 161 | 17,3 % | -8,29 % |
Small Molecules
13,4
%
| 819 | 13,2 % | 901 | 13,4 % | +10,01 % |
Cell & Gene
10,4
%
| 693 | 11,1 % | 696 | 10,4 % | +0,43 % |
Corporate/Eliminations
3,6
%
| 171 | 2,7 % | 240 | 3,6 % | +40,35 % |
Ventas por región
CHF en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
31,8
%
| 2 415 | 38,8 % | 2 136 | 31,8 % | -11,55 % |
Switzerland
17,4
%
| 996 | 16,0 % | 1 168 | 17,4 % | +17,27 % |
Japan
8,1
%
| 227 | 3,6 % | 544 | 8,1 % | +139,65 % |
Ireland
5,5
%
| 343 | 5,5 % | 368 | 5,5 % | +7,29 % |
Belgium
5,1
%
| 302 | 4,9 % | 341 | 5,1 % | +12,91 % |
Denmark
4,8
%
| 158 | 2,5 % | 322 | 4,8 % | +103,80 % |
Germany
4,5
%
| 224 | 3,6 % | 302 | 4,5 % | +34,82 % |
Rest of Europe
2,9
%
| 207 | 3,3 % | 195 | 2,9 % | -5,80 % |
China
2,6
%
| 161 | 2,6 % | 172 | 2,6 % | +6,83 % |
United Kingdom
2,5
%
| 139 | 2,2 % | 171 | 2,5 % | +23,02 % |
Singapore
2,0
%
| 113 | 1,8 % | 137 | 2,0 % | +21,24 % |
Sweden
1,8
%
| 143 | 2,3 % | 123 | 1,8 % | -13,99 % |
France
1,7
%
| 116 | 1,9 % | 111 | 1,7 % | -4,31 % |
South Korea
1,4
%
| 141 | 2,3 % | 97 | 1,4 % | -31,21 % |
Canada
1,3
%
| 63 | 1,0 % | 90 | 1,3 % | +42,86 % |
Netherlands
1,3
%
| 132 | 2,1 % | 88 | 1,3 % | -33,33 % |
Brazil
1,1
%
| 49 | 0,8 % | 71 | 1,1 % | +44,90 % |
Italy
0,8
%
| 41 | 0,7 % | 52 | 0,8 % | +26,83 % |
India
0,6
%
| 42 | 0,7 % | 42 | 0,6 % | 0,00 % |
Spain
0,6
%
| 41 | 0,7 % | 40 | 0,6 % | -2,44 % |
Mexico
0,5
%
| 34 | 0,5 % | 33 | 0,5 % | -2,94 % |
Rest of Asia
0,4
%
| 36 | 0,6 % | 29 | 0,4 % | -19,44 % |
Rest of Latin America
0,4
%
| 38 | 0,6 % | 26 | 0,4 % | -31,58 % |
Australia & New Zealand
0,2
%
| 21 | 0,3 % | 16 | 0,2 % | -23,81 % |
Thailand
0,2
%
| 15 | 0,2 % | 15 | 0,2 % | 0,00 % |
Indonesia
0,2
%
| 16 | 0,3 % | 14 | 0,2 % | -12,50 % |
Czech Republic
0,2
%
| 7 | 0,1 % | 11 | 0,2 % | +57,14 % |
Other Countries
0,0
%
| 2 | 0,0 % | 2 | 0,0 % | 0,00 % |
Rest of North and Central America
0,0
%
| 1 | 0,0 % | 1 | 0,0 % | 0,00 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Albert Baehny
CEO | Chief Executive Officer | 72 | 25/04/17 |
Philippe Deecke
DFI | Director of Finance/CFO | 52 | 01/12/21 |
Maria Nunez
COO | Chief Operating Officer | 55 | 01/08/22 |
Lyle Wheeler
IRC | Investor Relations Contact | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Barbara Richmond
BRD | Director/Board Member | 63 | 16/04/14 |
Director/Board Member | 66 | 16/04/14 | |
Marion Helmes
BRD | Director/Board Member | 58 | 05/05/22 |
Albert Baehny
CEO | Chief Executive Officer | 72 | 25/04/17 |
Christoph Mäder
BRD | Director/Board Member | 64 | 26/04/16 |
Roger Nitsch
BRD | Director/Board Member | 63 | 01/05/22 |
Director/Board Member | 64 | 04/05/18 | |
Director/Board Member | 52 | 04/05/18 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 72 226 184 | 69 832 097 ( 96,69 %) | 2 352 163 ( 3,257 %) | 96,69 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
LONZA GROUP AG 3.16% | 2 352 163 | 3.16% | 1 268 183 853 $ |
Información de la empresa
![Dirección Lonza Group AG(LO3A)](https://cdn.zonebourse.com/static/address/107428138.png)
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Arch Protection Chemicals Pvt Ltd.
![]() Arch Protection Chemicals Pvt Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Lonza Group AG, Arch Protection Chemicals Pvt Ltd. is an Indian company that provides business services. The company is based in Mumbai, India. |
Miscellaneous Commercial Services
|
Capsugel Germany GmbH
| |
Lonza Swiss Finanz AG
![]() Lonza Swiss Finanz AG Finance/Rental/LeasingFinance Lonza Swiss Finanz AG engages in the provision of financing services within the companies of Lonza Group AG. It also invests in domestic and foreign industrial and commercial firms. The company was founded on December 23, 1974 and is headquartered in Basel, Switzerland. |
Finance/Rental/Leasing
|
Arxada AG
![]() Arxada AG Chemicals: Major DiversifiedProcess Industries Arxada AG is a Swiss specialty chemicals company that offers consumer microbial control, industrial microbial control, and specialty product solutions. The company is based in Basel, CH, and has subsidiaries in the Netherlands, United States, and Thailand. The company provides a wide range of differentiated products for various end markets, including hygiene, home and personal care, wood protection, crop protection, and food, beverage, and water. Arxada has leading regulatory capabilities, IP expertise, and an established track record in the industry. C. Marc Doyle has been the CEO of the company since 2021. |
Chemicals: Major Diversified
|
Capsugel FinanceCo SARL
| |
Xcelience Clinical Services Ltd.
![]() Xcelience Clinical Services Ltd. Miscellaneous Commercial ServicesCommercial Services Part of MW Encap (Holdings) Ltd., Xcelience Clinical Services Ltd. provides packaging services. The company is based in London, UK. |
Miscellaneous Commercial Services
|
Capsugel Plöermel SASU
![]() Capsugel Plöermel SASU BiotechnologyHealth Technology Capsugel Plöermel SASU designs and manufactures biopharmaceuticals. The company is headquartered in Ploermel, France. |
Biotechnology
|
Capsugel Belgium SA
![]() Capsugel Belgium SA Pharmaceuticals: MajorHealth Technology Capsugel Belgium NV provides dosage forms and solutions. The firm also sells equipment for filling empty and liquid capsules and equipment for sealing liquid capsules. The company was founded on October 1, 1961 and is headquartered in Bornem, Belgium. |
Pharmaceuticals: Major
|
Capsugel Italy SRL
![]() Capsugel Italy SRL Miscellaneous Commercial ServicesCommercial Services Part of Chester Investor Holdings SRL, Capsugel Italy SRL provides management consulting services. The company is based in Milan, Italy. |
Miscellaneous Commercial Services
|
Sector
Ventas por actividad
Ventas por región
![Consenso](/images/consensus_flch.gif)
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+19,41 % | 45,51 mil M | |
-8,62 % | 38,52 mil M | |
+26,95 % | 30,74 mil M | |
-13,50 % | 26,03 mil M | |
+10,74 % | 25,92 mil M | |
+44,87 % | 14,13 mil M | |
+34,36 % | 12,73 mil M | |
-7,14 % | 11,29 mil M | |
-12,61 % | 10,64 mil M |
- Bolsa de valores
- Acciones
- Acción LONN
- Acción LO3A
- Empresa Lonza Group AG